TRML Stock Forecast 2025-2026
Distance to TRML Price Targets
TRML Price Momentum
10 Quality Stocks Worth Considering Now
Researching Tourmaline Bio (TRML) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TRML and similar high-potential opportunities.
Latest TRML Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, TRML has a bullish consensus with a median price target of $55.00 (ranging from $43.00 to $74.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $18.80, the median forecast implies a 192.6% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robyn Karnauskas at Truist Securities, projecting a 293.6% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 128.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TRML Analyst Ratings
TRML Price Target Range
Latest TRML Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TRML.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $43.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $50.00 |
| Mar 6, 2025 | Wedbush | Laura Chico | Outperform | Initiates | $42.00 |
| Feb 24, 2025 | LifeSci Capital | Jimmy Shan | Outperform | Initiates | $58.00 |
| Dec 11, 2024 | Guggenheim | Yatin Suneja | Buy | Reiterates | $0.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $25.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $49.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $50.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $49.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| May 14, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| Mar 25, 2024 | Truist Securities | Robyn Karnauskas | Buy | Reiterates | $74.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| Mar 20, 2024 | Jefferies | Roger Song | Buy | Maintains | $72.00 |
| Dec 15, 2023 | Jefferies | Roger Song | Buy | Initiates | $41.00 |
| Nov 17, 2023 | Truist Securities | Robyn Karnauskas | Buy | Initiates | $43.00 |
| Oct 31, 2023 | Guggenheim | Yatin Suneja | Buy | Initiates | $50.00 |
| Oct 25, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $65.00 |
| Apr 17, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
| Feb 23, 2023 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $3.00 |
Tourmaline Bio Inc. (TRML) Competitors
The following stocks are similar to Tourmaline Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tourmaline Bio Inc. (TRML) Financial Data
Tourmaline Bio Inc. has a market capitalization of $482.89M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -27.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Tourmaline Bio Inc. (TRML) Business Model
About Tourmaline Bio Inc.
Biotechnology company developing therapies for immune-inflammatory diseases.
Tourmaline Bio Inc. generates revenue by advancing its pipeline of novel therapeutic candidates through clinical trials aimed at immune-inflammatory diseases. By focusing on areas with significant unmet medical needs, the company seeks to create innovative therapies that can be marketed to healthcare providers and patients, thus establishing a sustainable business model.
The company's emphasis on research and development positions it as a leader in the biotechnology sector, especially in biologics and precision therapies. Strategic partnerships enhance its ability to bring transformative therapies to market, indicating strong potential for growth and impact within the healthcare industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Sandeep C. Kulkarni M.D.
Country
United States
IPO Year
2023
Website
www.tourmalinebio.comTourmaline Bio Inc. (TRML) Latest News & Analysis
The Phase 2 TRANQUILITY trial has enrolled 143 participants, aiming for topline data by Q2 2025. The Cardiovascular Advisory Board has added Drs. Bhatt, Gill, and Paul M.
The over-enrollment in the TRANQUILITY trial signals strong interest and potential for positive outcomes, while new advisory board appointments enhance credibility and strategic direction.
Tourmaline Bio, Inc. (NASDAQ: TRML) announced CEO Sandeep Kulkarni will participate in an upcoming investor conference, focusing on its late-stage clinical developments for immune and inflammatory diseases.
Leadership participation in investor conferences can signal confidence in the company's progress and attract investor interest, potentially impacting stock performance.
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
2 months agoTourmaline Bio, Inc. (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board, enhancing its expertise in developing treatments for immune and inflammatory diseases.
The appointment of a prominent figure like Dr. Paul M. Ridker to Tourmaline's advisory board may enhance the company's credibility and strategic direction, potentially boosting investor confidence and stock performance.
Tourmaline Bio has enrolled 143 patients in its Phase 2 TRANQUILITY trial, with topline data expected in Q2 2025. The company is expanding its cardiovascular focus by nominating a new indication for pacibekitug.
Successful enrollment in the TRANQUILITY trial and adding new advisors highlight Tourmaline Bio's advancing pipeline, potentially boosting investor confidence and stock value ahead of key data in 2025.
Tourmaline Bio, Inc. (NASDAQ: TRML) will host a virtual Investor Day on December 10, 2024, featuring presentations from its leadership team and Dr. Marc Bonaca.
Tourmaline Bio's Investor Day may provide insights into its pipeline and strategic direction, potentially influencing stock performance and investor sentiment in the biotech sector.
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
4 months agoTourmaline Bio plans to report Phase 2 trial data in H1 2025 and has $314.4M cash on hand, ensuring funding through 2027. A Cardiovascular Scientific Advisory Board was formed in October 2024.
Tourmaline Bio’s upcoming Phase 2 trial results and strong cash position suggest potential growth and sustained operations, making it a stock to watch for biotech investors.
Frequently Asked Questions About TRML Stock
What is Tourmaline Bio Inc.'s (TRML) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Tourmaline Bio Inc. (TRML) has a median price target of $55.00. The highest price target is $74.00 and the lowest is $43.00.
Is TRML stock a good investment in 2025?
According to current analyst ratings, TRML has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TRML stock?
Wall Street analysts predict TRML stock could reach $55.00 in the next 12 months. This represents a 192.6% increase from the current price of $18.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tourmaline Bio Inc.'s business model?
Tourmaline Bio Inc. generates revenue by advancing its pipeline of novel therapeutic candidates through clinical trials aimed at immune-inflammatory diseases. By focusing on areas with significant unmet medical needs, the company seeks to create innovative therapies that can be marketed to healthcare providers and patients, thus establishing a sustainable business model.
What is the highest forecasted price for TRML Tourmaline Bio Inc.?
The highest price target for TRML is $74.00 from Robyn Karnauskas at Truist Securities, which represents a 293.6% increase from the current price of $18.80.
What is the lowest forecasted price for TRML Tourmaline Bio Inc.?
The lowest price target for TRML is $43.00 from Laura Chico at Wedbush, which represents a 128.7% increase from the current price of $18.80.
What is the overall TRML consensus from analysts for Tourmaline Bio Inc.?
The overall analyst consensus for TRML is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $55.00.
How accurate are TRML stock price projections?
Stock price projections, including those for Tourmaline Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
